|
|
 |
|
Viewing report
|
|
|
|
Psychiatric Drugs: New Developments and Market Analysis by Drug Class and Clinical Indication
Drug and Market Development Publishing, Nov 2004, Pages: 250
Chapter 1: Executive Summary 1–1
Introduction & Purpose 1–1
Organization 1–1
General Findings 1–2
Selected Highlights 1–4
Antipsychotic Drug Classes 1–4
Antidepressant Drug Classes 1–4
Anti-Anxiety Drug Classes 1–5
Antidepressant/Anti-Anxiety Drugs in Development 1–6
Sleep-Promoting Drugs 1–6
Wake-Promoting Drugs 1–6
Cognition-/Memory-Enhancing Drug Classes 1–7
Anti-Obesity Drug Classes 1–7
Antiepileptics (AEDs) for Psychiatric Indications 1–8
Substance and Alcohol Dependence Drug Classes 1–8
Chapter 2: Drug Class Analysis 2–1
Antipsychotic Drug Classes 2–1
R&D Trends and Drugs in Development 2–1
Clinical Applications 2–7
Market Drivers and Analysis 2–8
Selected References: 2–13
Antidepressant Drug Classes 2–13
R&D Trends and Drugs in Development 2–13
Clinical Applications 2–22
Market Drivers and Analysis 2–22
Anti-Anxiety Drug Classes 2–26
R&D Trends and Drugs in Development 2–26
Clinical Applications 2–32
Market Drivers and Analysis 2–32
Depression-Anxiety Drug Development by Drug Class 2–32
Sleep-Promoting Drugs 2–42
R&D Trends and Drugs in Development 2–42
Clinical Applications 2–45
Market Drivers and Analysis 2–45
Selected References: 2–46
Wake-Promoting Drugs 2–47
R&D Trends and Drugs in Development 2–47
Clinical Applications 2–49
Market Drivers and Analysis 2–49
Seleteced References: 2–50
Cognition-/Memory-Enhancing Drug Classes 2–51
R&D Trends and Drugs in Development 2–51
Clinical Applications 2–57
Market Drivers and Analysis 2–57
Selected References 2–57
Anti-Obesity Drug Classes 2–58
R&D Trends and Drugs in Development 2–58
Clinical Applications 2–63
Market Drivers and Analysis 2–63
Selected References: 2–64
Antiepileptics (for psychiatric disorders) 2–65
R&D Trends and Drugs in Development 2–65
Market and Trends 3–29
Wake Disorders 3–30
Overview 3–30
Current Pharmacotherapy and Trends 3–31
Market and Trends 3–31
Obesity and Related Disorders 3–31
Overview 3–31
Current Pharmacotherapy and Trends 3–32
Market and Trends 3–34
Attention Deficit Hyperactivity Disorder 3–34
Overview 3–34
Current Pharmacotherapy and Trends 3–35
Market and Trends 3–35
Chapter 4: Company Profiles 4–1
Abbott Laboratories, Inc 4–2
Addex Pharmaceuticals SA 4–3
Alkermes, Inc 4–4
Amarin Corporation plc 4–5
AstraZeneca PLC 4–6
Avanir Pharmaceuticals, Inc 4–7
Aventis, Aventis Pasteur 4–8
Axonyx, Inc 4–9
Boehringer Ingelheim GmbH 4–10
Bristol-Myers Squibb Co 4–11
Celltech Group plc 4–12
Cephalon, Inc 4–13
Cortex Pharmaceuticals, Inc 4–15
Dainippon 4–16
DOV Pharmaceutical, Inc 4–17
DrugAbuse Pharmaceuticals, Inc 4–18
Elan Corporation plc 4–19
Eli Lilly and Company 4–20
Forest Laboratories, Inc 4–22
GB Therapeutics, Ltd 4–24
GlaxoSmithKline plc 4–25
Helicon Therapeutics, Inc 4–28
Indevus Pharmaceuticals, Inc 4–29
Innapharma, Inc 4–30
Johnson & Johnson (including Janssen Pharmaceutica,
Janssen-CilagAlza, Ortho-McNeil) 4–31
Laxdale, Ltd 4–33
Lundbeck (H Lundbeck A/S) 4–34
Clinical Applications 2–69
Market Drivers and Analysis 2–69
Substance and Alcohol Dependence Drug Classes 2–71
R&D Trends and Drugs in Development 2–71
Clinical Applications 2–78
Market Drivers and Analysis 2–78
Chapter 3: Schizophrenia and Other Psychotic Disorders 3–1
Overview 3–1
Current Pharmacotherapy and Trends 3–2
Market and Trends 3–4
Depressive Disorders 3–4
Overview 3–4
Current Pharmacotherapy and Trends 3–7
Market and Trends 3–8
Bipolar Disorder 3–9
Overview 3–9
Current Pharmacotherapy and Trends 3–11
Market and Trends 3–12
Anxiety Disorders 3–12
Overview 3–12
Current Pharmacotherapy and Trends 3–15
Market and Trends 3–19
Cognitive Disorders 3–19
Overview 3–19
Current Pharmacotherapy and Trends 3–20
Market and Trends 3–23
Sleep Disorders 3–24
Overview 3–24
Current Pharmacotherapy and Trends 3–26
TABLE OF EXHIBITS
Exhibit 2 1 Selected Antipsychotic Drugs in Development 2–4
Exhibit 2 2 Launched Antipsychotics: Recent Developments 2–6
Exhibit 2 3 Factors Driving Development of New Antipsychotic Drugs 2–11
Exhibit 2 4 Antidepressant Drug Classes 2–14
Exhibit 2 5 Antidepressant Drugs in Development* 2–18
Exhibit 2 6 Anxiety Disorders: Neurobiology/Pathophysiology References 2–27
Exhibit 2 7 Selected Neurobiologic/Pathophysiologic Findings in Anxiety Disorders 2–28
Exhibit 2 8 Drugs in Development for the Treatment of Anxiety* 2–29
Exhibit 2 9 Antidepressant/Anti-anxiety Drug Development:
Serotonin-Only Mechanisms 2–34
Exhibit 2 10 Antidepressant/Anti-anxiety Drug Development:
Adrenergic-Only Mechanisms 2–35
Exhibit 2 11 Antidepressant/Anti-anxiety Drug Development:
Serotonin + Norepinephrine Mechanisms 2–36
Exhibit 2 12 Antidepressant/Anti-anxiety Drug Development:
Serotonin + Dopamine Mechanisms 2–36
Exhibit 2 13 Antidepressant/Anti-anxiety Drug Development:
Serotonin + Dopamine + Norepinephrine Mechanisms 2–37
Exhibit 2 14 Antidepressant / Anti-anxiety Drug Development:
Monoamine Oxidase Mechanisms 2–37
Exhibit 2 15 Antidepressant/Anti-anxiety Drug Development: Corticotropin-Releasing
Factor (CRF) Antagonist Mechanisms 2–38
Exhibit 2 16 Antidepressant/Anti-anxiety Drug Development:
Neurokinin (NK)/ Substance P (SP) Antagonist Mechanisms 2–39
Exhibit 2 17 Antidepressant/Anti-Anxiety Drug Development: GABA Mechanisms 2–40
Exhibit 2 18 Antidepressant/Anti-anxiety Drug Development: Other Mechanisms 2–41
Exhibit 2 19 Selected Sleep-Promoting Drugs in Development 2–44
Exhibit 2 20 Wake-Promoting Drugs: Selected Recent Developments 2–48
Exhibit 2 21 Selected Developmental Drugs With Cognitive-Enhancing Potential 2–54
Exhibit 2 22 Selected Drugs in Development for the Treatment of Obesity* 2–61
Exhibit 2 23 Antiepileptic Drug Development: Selected Recent Developments* 2–66
Exhibit 2 24 Selected Approved Drugs and Therapies in Clinical Trials for
Substance and Alcohol Abuse1 2–75
Exhibit 2 25 Selected Drugs in Development for Alcoholism and Drug Addiction 2–77
Exhibit 3 1 Antidepressant Approaches in Development 3–8
Exhibit 3 2 Epidemiology of Anxiety Disorders 3–15
Exhibit 3 3 Drug Classes Used to Treat Anxiety Disorders* 3–16
Exhibit 3 4 Current Pharmacotherapy of Specific Anxiety Disorders 3–17
Exhibit 3 5 Insomnia: Current Practices and Treatments 3–27
Exhibit 3 6 Current Pharmacologic Treatment of ADHD 3–35
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Pharmacogenomics for Clinical Use and in Drug Development
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
Emerging Diagnostic Technologies for Use in Psychiatric Indications
Pain Therapeutics - Drugs, Markets and Companies
Anxiety Disorders - A Decade of Declining Revenues
Infectious Diseases Drugs Markets
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Neuroprotection - Drugs, Markets and Companies
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Handbook of Psychiatric Drugs
Drugs in the Pipeline--An R&D Analysis
|
|
|
|
